TNFRSF17 and Miyoshi myopathy: TNFRSF17 encodes the antigen BCMA, which is used as target in several immunotherapies for MM patients and biallelic genomic loss of TNFRSF17 has been described as resistance mechanism to BCMA-targeted immunotherapies [23, 24].